世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ウイルスベクター・プラスミドDNA製造市場：タイプ別（ウイルスベクター（レトロウイルス、アデノウイルス、AAV、レンチウイルス）、プラスミドDNA）、ワークフロー別（上流、下流）、用途別（細胞・遺伝子治療）、疾患別（癌）、エンドユーザー別 - 2028年までの世界予測


Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028

世界のウイルスベクターおよびプラスミドDNA製造市場は、2023年の55億米ドルから2028年には128億米ドルに達し、2023年から2028年の予測期間中に18.2％のCAGRで成長すると予測されている。この市場の成長は、遺伝... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年6月12日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		317 413 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界のウイルスベクターおよびプラスミドDNA製造市場は、2023年の55億米ドルから2028年には128億米ドルに達し、2023年から2028年の予測期間中に18.2％のCAGRで成長すると予測されている。この市場の成長は、遺伝子治療の開発資金が確保されていることに起因している。遺伝子治療は急速に成長している分野であり、研究開発、臨床試験、製造には資金が必要である。例えば、2022年12月、バイオテクノロジー企業のSonoThera社は、6075万米ドルのシリーズA資金調達ラウンドの完了を発表した。この資金調達は、患者に遺伝子医薬品を提供するために設計された、SonoThera社の超音波ガイド下、非ウイルス、遺伝子治療プラットフォームと治療法の継続的開発を支援する。

"予測期間中、ベクター増幅・編集・拡張セグメントが上流製造工程別で最大のシェアを占める"
2022年、世界のウイルスベクター・プラスミドDNA製造市場において、ベクター増幅・編集・拡張セグメントが上流製造工程別で最大のシェアを占めた。ベクターの増幅、編集、拡張は、ベクターの量、品質、機能性に直接影響するため、ウイルスベクターおよびプラスミドDNA製造における重要な工程である。製薬・バイオ医薬品業界は、特に新規治療薬やワクチンの開発において著しい進歩を遂げている。ウイルスベクターやプラスミドDNAは、治療用遺伝子やワクチン抗原を送達するための重要なツールである。ベクターの増幅、編集、拡張の需要は、様々な治療薬やワクチン候補のための多様なウイルスベクターやプラスミドDNAを生産する必要性によってもたらされている。

「ヨーロッパウイルスベクターとプラスミドDNA製造市場で2番目に大きい地域"
欧州は、ウイルスベクター・プラスミドDNA製造市場において、北米に次いで2番目に大きな市場を占めている。欧州のウイルスベクター・プラスミドDNA製造市場は、その拡大を後押しする様々な要因によって、近年著しい成長を遂げている。欧州は、ウイルスベクター・プラスミドDNA製造市場において、新技術の開発・導入の最前線にある。これには、ウイルスベクターおよびプラスミドDNA製造技術の進歩も含まれる。これらの革新的技術の採用は、ウイルスベクターおよびプラスミドDNA製造研究の進展を加速し、その応用を拡大する。さらに欧州では、ウイルスベクターおよびプラスミドDNA製造に関する包括的なトレーニングおよび教育プログラムを提供している。大学、研究機関、組織が資金を提供し、科学者や研究者の知識や技能を高めるための会議が開かれている。このような資金援助により、欧州ではウイルスベクターおよびプラスミドDNA製造技術の採用と利用が促進されている。

本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側70％、需要側30
- 役職別Cレベル45％、Dレベル30％、その他25
- 地域別北米40％、欧州25％、アジア太平洋地域20％、中南米10％、中東・アフリカ5
レポート掲載企業リスト
- ロンザ・グループ（スイス）
- サーモフィッシャーサイエンティフィック（米国）
- メルクKGaA（ドイツ）
- オックスフォード・バイオメディカ（英国）
- 富士フイルム (日本)
- チャールズ・リバー・ラボラトリーズ・インターナショナル（米国）
- ダナハーコーポレーション（米国）
- ジェンスクリプト・バイオテック（米）
- SIRION BIOTECH (ドイツ)
- キャタレント社（米国）
- ノバルティスAG（スイス）
- プレシジョン・バイオサイエンシズ（米国）
- タカラバイオ（日本）
- ブルーバードバイオ（米国）
- ザルトリウスAG（ドイツ）
- VGXI, INC（米国）
- ワイズマン・バイオマニュファクチャリング（米国）
- Kaneka Eurogentec S.A.（ベルギー）
- プラスミドファクトリー社（ドイツ）
- ウーシー・アプテック（中国）
- アトゥム（米国）
- アドジーン（米国）
- セル・アンド・ジーン・セラピー・カタパルト（米国）
- Batavia Biosciences B.V.（オランダ）
- アルトジェン・バイオシステムズ（米）

調査範囲
この調査レポートは、ウイルスベクターとプラスミドDNA製造市場の詳細な姿を提供しています。タイプ、製品＆サービス、ワークフロー、アプリケーション、疾患適応症、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主な利点
本レポートは、市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（遺伝性疾患、癌、感染症の有病率の上昇、遺伝子治療開発のための資金調達の可能性、ウイルスベクターの有効性、ウイルスベクターベースの遺伝子・細胞治療に関する進行中の研究）、阻害要因（細胞・遺伝子治療製造に関連する高い運用コスト、ウイルスベクターの短い保存可能期間）の分析、機会（スマートな資本展開と拡張性のための計画、オペレーショナル・エクセレンスを促進するためのデジタルの活用）、および課題（突然変異誘発やその他の望ましくない結果のリスク、個々の最適化と低い収率が下流工程の足かせとなっている）が市場の成長に影響を及ぼしている。
- 製品とサービスの開発/革新：新発売の製品・サービスに関する詳細な洞察、ウイルスベクター・プラスミドDNA製造市場の技術評価
- 市場開発：有利な市場に関する包括的な情報 - 当レポートは様々な地域の市場を分析しています。
- 市場の多様化：ウイルスベクターとプラスミドDNA製造市場における新製品とサービス、未開拓の地域、最近の開発、投資に関する網羅的な情報
- 競合評価：Lonza Group AG（スイス）、Merck KGaA（ドイツ）、Thermo Fisher Scientific Inc.（米国）、Charles River Laboratories International, Inc.（米国）、Catalent Inc.（米国）、WuXi AppTec（中国）、富士フイルム株式会社（日本）、GenScript Biotech Corporation（米国）、Takara Bio Inc.(日本）、Oxford Biomedica（英国）、Novartis AG（スイス）、Precision Biosciences（米国）、Bluebird Bio, Inc.（米国）、Sartorius AG（ドイツ）、Danaher Corporation（米国）、SIRON Biotech（ドイツ）、VGXI, Inc.（米国）、Waisman Biomanufacturing（米国）、Kaneka Eurogentec S.A.（ベルギー）、PlasmidFactory GmbH（ドイツ）、ATUM（米国）、Addgene（米国）、Cell and Gene Therapy Catapult（英国）、Batavia biosciences（オランダ）、Altogen Biosystems（米国）などである。

ページTOPに戻る


目次

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.2.1 INCLUSIONS AND EXCLUSIONS 47
1.3 MARKET SCOPE 48
FIGURE 1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION 48
1.3.1 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 49
1.5 LIMITATIONS 49
1.6 STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 50
1.7.1 RECESSION IMPACT 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH APPROACH 52
FIGURE 2 RESEARCH DESIGN 52
2.1.1 SECONDARY RESEARCH 53
2.1.2 PRIMARY DATA 53
FIGURE 3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES 54
2.2 MARKET SIZE ESTIMATION 55
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022 55
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 56
FIGURE 6 ILLUSTRATIVE EXAMPLE OF LONZA GROUP AG: REVENUE SHARE ANALYSIS (2022) 56
2.2.1 INSIGHTS FROM PRIMARIES 58
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 58
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 58
2.3 GROWTH FORECAST 59
FIGURE 9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: CAGR PROJECTIONS 60
FIGURE 10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 11 DATA TRIANGULATION METHODOLOGY 61
2.5 RESEARCH ASSUMPTIONS 62
2.6 RISK ANALYSIS 62
2.7 RECESSION IMPACT ANALYSIS 62
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 62
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 63
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 63
3 EXECUTIVE SUMMARY 64
FIGURE 12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 64
FIGURE 13 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 65
FIGURE 14 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2023 VS. 2028 (USD MILLION) 65
FIGURE 15 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 66
FIGURE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION) 67
FIGURE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 67
FIGURE 18 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT 68
4 PREMIUM INSIGHTS 70
4.1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET OVERVIEW 70
FIGURE 19 ONGOING RESEARCH ON VIRAL VECTOR-BASED CELL AND GENE THERAPIES TO DRIVE MARKET 70
4.2 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: NORTH AMERICA, BY PRODUCT & SERVICE AND COUNTRY 71
FIGURE 20 PRODUCTS SEGMENT IN US ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 71
4.3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 71
FIGURE 21 PRODUCTS SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 71
4.4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SHARE, BY END USER (2022) 72
FIGURE 22 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 72
4.5 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 72
FIGURE 23 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 72
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 73
FIGURE 24 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 73
TABLE 4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 74
5.2.1 DRIVERS 74
5.2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases 74
5.2.1.2 Availability of funding for development of gene therapy 75
5.2.1.3 Effectiveness of viral vectors 76
5.2.1.4 Ongoing research on viral vector-based gene and cell therapies 76
TABLE 5 OVERVIEW OF CURRENT CLINICAL TRIALS BASED ON VECTOR TYPE 76
5.2.2 RESTRAINTS 77
5.2.2.1 High operational costs associated with cell and gene therapy manufacturing 77
5.2.2.2 Short shelf life of viral vectors 77
5.2.3 OPPORTUNITIES 78
5.2.3.1 Smart capital deployment and planning for scalability 78
5.2.3.2 Leveraging digital tools to facilitate operational excellence 78
5.2.4 CHALLENGES 79
5.2.4.1 Risk of mutagenesis and other unwanted outcomes 79
5.2.4.2 Individual optimization and low yield 79
5.3 INDICATIVE PRICING ANALYSIS 79
TABLE 6 PRICING ANALYSIS FOR PRODUCTS 80
5.4 VALUE CHAIN ANALYSIS 81
5.5 VALUE CHAIN ANALYSIS: MANUFACTURING PHASES ADD MAXIMUM VALUE 82
5.5.1 ECOSYSTEM ANALYSIS 82
FIGURE 25 ECOSYSTEM ANALYSIS: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 83
TABLE 7 OVERALL MARKET ECOSYSTEM FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 84
5.6 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.6.1 THREAT OF NEW ENTRANTS 86
5.6.2 THREAT OF SUBSTITUTES 86
5.6.3 BARGAINING POWER OF BUYERS 86
5.6.4 BARGAINING POWER OF SUPPLIERS 86
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.7 TECHNOLOGY ANALYSIS 87
TABLE 9 EXAMPLES OF ADVANCED PRODUCTS/PLATFORMS 87
5.8 PATENT ANALYSIS 88
FIGURE 26 TOP PATENT OWNERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, JANUARY 2014 TO JANUARY 2023 88
TABLE 10 EXAMPLES OF RECENT PATENT ACTIVITY IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 88
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURERS 89
5.10 REGULATORY ANALYSIS 90
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 94
TABLE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: LIST OF CONFERENCES AND EVENTS 94
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 95
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS 96
5.12.2 BUYING CRITERIA FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS AND SERVICES 96
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 97
6 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE 98
6.1 INTRODUCTION 99
TABLE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 99
6.2 VIRAL VECTOR 99
TABLE 18 VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 19 VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 20 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 21 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 22 ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 23 LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.2.1 RETROVIRUS 102
6.2.1.1 Rising application of retroviruses in gene therapy and gene transfer studies to support growth 102
TABLE 24 RETROVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 25 NORTH AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 26 EUROPE: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 27 ASIA PACIFIC: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 28 LATIN AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.2.2 ADENOVIRUS 104
6.2.2.1 Large capacity for carrying genetic material to promote growth 104
TABLE 29 ADENOVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 30 NORTH AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 31 EUROPE: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 32 ASIA PACIFIC: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 33 LATIN AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
6.2.3 ADENO-ASSOCIATED VIRUS 106
6.2.3.1 Low toxicity to support demand growth 106
TABLE 34 AAV VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 35 NORTH AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 36 EUROPE: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 37 ASIA PACIFIC: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 38 LATIN AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.2.4 LENTIVIRUS 108
6.2.4.1 Ability to infect both dividing and non-dividing cells to drive growth 108
TABLE 39 LENTIVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 40 NORTH AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 41 EUROPE: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 42 ASIA PACIFIC: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 43 LATIN AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.2.5 OTHER VIRAL VECTORS 110
TABLE 44 OTHER VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 45 NORTH AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 46 EUROPE: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 47 ASIA PACIFIC: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 48 LATIN AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
6.3 PLASMID DNA 113
6.3.1 GROWING R&D AND LAUNCHES OF PRODUCTION PLATFORMS TO BOOST MARKET 113
TABLE 49 PLASMID DNA MANUFACTURING MARKET, BY REGION 2021–2028 (USD MILLION) 113
TABLE 50 NORTH AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 51 EUROPE: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 53 LATIN AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
7 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE 115
7.1 INTRODUCTION 116
TABLE 54 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
7.2 PRODUCTS 116
7.2.1 INCREASING PRODUCT LAUNCHES TO DRIVE MARKET GROWTH 116
TABLE 55 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS, BY KEY PLAYER 117
TABLE 56 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 57 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 58 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 59 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 60 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
7.3 SERVICES 119
7.3.1 INCREASING DEMAND FOR SERVICES TO BOOST MARKET 119
TABLE 61 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES, BY KEY PLAYER 120
TABLE 62 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 63 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 64 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW 123
8.1 INTRODUCTION 124
TABLE 67 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 124
8.2 UPSTREAM MANUFACTURING 124
TABLE 68 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 125
TABLE 69 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 70 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 71 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 72 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 73 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
8.2.1 VECTOR AMPLIFICATION, EDITING, AND EXPANSION 127
8.2.1.1 Increasing demand for gene therapy to fuel growth 127
TABLE 74 VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 75 NORTH AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 76 EUROPE: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 77 ASIA PACIFIC: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 LATIN AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
8.2.2 VECTOR RECOVERY/HARVESTING 129
8.2.2.1 Rising clinical trials and approvals of cell and gene-based therapies to drive demand for vector recovery/harvesting 129
TABLE 79 VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 80 NORTH AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 81 EUROPE: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 ASIA PACIFIC: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 LATIN AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
8.3 DOWNSTREAM MANUFACTURING 131
TABLE 84 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 132
TABLE 85 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY REGION 2021–2028 (USD MILLION) 132
TABLE 86 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 87 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 88 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 89 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
8.3.1 PURIFICATION 134
8.3.1.1 Technological advancements in purification to drive market 134
TABLE 90 PURIFICATION PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 91 NORTH AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 92 EUROPE: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 93 ASIA PACIFIC: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 94 LATIN AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
8.3.2 FILL-FINISH 136
8.3.2.1 Technological advancements in downstream manufacturing process 136
TABLE 95 FILL-FINISH PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 96 NORTH AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 97 EUROPE: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 98 ASIA PACIFIC: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 99 LATIN AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION 139
9.1 INTRODUCTION 140
TABLE 100 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
9.2 CELL & GENE THERAPY 140
9.2.1 ROBUST PIPELINE FOR CELL & GENE THERAPY TO DRIVE MARKET 140
TABLE 101 NUMBER OF CELL AND GENE THERAPIES IN CLINICAL TRIAL PHASES (2021) 141
TABLE 102 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 103 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 104 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 105 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 106 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
9.3 VACCINE DEVELOPMENT 143
9.3.1 DEVELOPMENT OF NOVEL VACCINES TO DRIVE DEMAND FOR VIRAL VECTORS AND PLASMID DNA 143
TABLE 107 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY REGION 2021–2028 (USD MILLION) 143
TABLE 108 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 109 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 110 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 111 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 145
9.4 RESEARCH 145
9.4.1 RISING R&D TO INTRODUCE NEW APPLICATIONS OF VIRAL VECTOR AND PLASMID DNA 145
TABLE 112 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY REGION 2021–2028 (USD MILLION) 145
TABLE 113 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 114 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 115 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 116 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 147
10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION 148
10.1 INTRODUCTION 149
TABLE 117 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 149
10.2 CANCER 149
10.2.1 INCREASING PATIENT POPULATION TO PROPEL MARKET GROWTH 149
TABLE 118 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 150
TABLE 119 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 150
TABLE 120 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 121 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 122 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 123 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 152
10.3 GENETIC DISORDERS 152
10.3.1 LAUNCH OF ADVANCED TOOLS TO DELIVER THERAPEUTIC GENES TO SUPPORT MARKET GROWTH 152
TABLE 124 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 125 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 126 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 127 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 128 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
10.4 INFECTIOUS DISEASES 154
10.4.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 154
TABLE 129 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 130 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 131 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 132 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 133 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
10.5 OTHER DISEASE INDICATIONS 157
TABLE 134 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 135 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 136 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 137 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 138 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
11 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER 159
11.1 INTRODUCTION 160
TABLE 139 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 160
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 160
11.2.1 GROWING CELL & GENE THERAPY R&D TO BOOST GROWTH 160
TABLE 140 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 141 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 142 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 143 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 144 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 163
11.3 ACADEMIC & RESEARCH INSTITUTES 163
11.3.1 INCREASING DRUG DISCOVERY RESEARCH PROGRAMS TO DRIVE MARKET 163
TABLE 145 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 146 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 147 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 148 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 149 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 165
11.4 OTHER END USERS 165
TABLE 150 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 151 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 152 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 153 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 154 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION 168
12.1 INTRODUCTION 169
TABLE 155 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 169
12.2 NORTH AMERICA 169
12.2.1 NORTH AMERICA: RECESSION IMPACT 170
FIGURE 30 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SNAPSHOT 171
TABLE 156 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 157 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 158 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 159 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 172
TABLE 160 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 173
TABLE 161 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 173
TABLE 162 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 173
TABLE 163 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 164 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 174
TABLE 165 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 174
12.2.2 US 175
12.2.2.1 Increasing incidence of cancer to propel market 175
TABLE 166 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 167 US: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 168 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 176
TABLE 169 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 176
TABLE 170 US: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 177
TABLE 171 US: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 177
TABLE 172 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 173 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 178
TABLE 174 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 178
12.2.3 CANADA 178
12.2.3.1 Government initiatives to promote research to support market growth 178
TABLE 175 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 176 CANADA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 177 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 178 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 180
TABLE 179 CANADA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 180
TABLE 180 CANADA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 181
TABLE 181 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 182 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 181
TABLE 183 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3 EUROPE 182
12.3.1 EUROPE: RECESSION IMPACT 182
TABLE 184 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 185 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 186 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 187 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 184
TABLE 188 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 184
TABLE 189 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 190 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 191 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 192 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 186
TABLE 193 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 186
12.3.2 GERMANY 186
12.3.2.1 Presence of large number of academic research institutes to propel market 186
TABLE 194 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 195 GERMANY: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 196 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 188
TABLE 197 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 188
TABLE 198 GERMANY: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 188
TABLE 199 GERMANY: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 189
TABLE 200 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
TABLE 201 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 189
TABLE 202 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 190
12.3.3 UK 190
12.3.3.1 Increasing R&D investments by pharmaceutical companies to support market 190
TABLE 203 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 204 UK: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 205 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 191
TABLE 206 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 192
TABLE 207 UK: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 192
TABLE 208 UK: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 192
TABLE 209 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 193
TABLE 210 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 193
TABLE 211 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 193

　

ページTOPに戻る


　

Summary

The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing. For instance, in December 2022, SonoThera, a biotechnology company announced completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.

“The vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process during the forecast period”
In 2022, vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors. The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens. The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.

“Europe: The second largest region in the viral vector and plasmid DNA manufacturing market”
Europe accounted for the second-largest market for viral vector and plasmid DNA manufacturing market after North America. The European viral vector and plasmid DNA manufacturing market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion. Europe is at the forefront of developing and adopting emerging technologies in the field of viral vector and plasmid DNA manufacturing market. This includes advancements in viral vector and plasmid DNA manufacturing gtechnologies. The adoption of these innovative technologies accelerates the progress of viral vector and plasmid DNA manufacturing research and expands its applications. Additionally, Europe offers comprehensive training and education programs in viral vector and plasmid DNA manufacturing. Universities, research institutes, and organizations provide funding, and conferences to enhance the knowledge and skills of scientists and researchers. The availability of funding promotes the adoption and utilization of of viral vector and plasmid DNA manufacturing technologies in Europe.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level - 45%, D-level - 30%, and Others - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%
List of Companies Profiled in the Report:
• Lonza Group (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Oxford Biomedica (UK)
• FUJIFILM Corporation (Japan)
• Charles River Laboratories International, Inc. (US)
• Danaher Corporation (US)
• Genscript Biotech Corporation (US)
• SIRION BIOTECH (Germany)
• Catalent, Inc (US)
• Novartis AG (Switzerland)
• Precision Biosciences (US)
• Takara Bio Inc. (japan)
• Bluebird Bio, Inc. (US)
• Sartorius AG (Germany)
• VGXI, INC. (US)
• Waisman Biomanufacturing (US)
• Kaneka Eurogentec S.A. (Belgium)
• PlasmidFactory GmbH (Germany)
• WuXi AppTec (China)
• Atum (US)
• Addgene (US)
• Cell and Gene Therapy Catapult (US)
• Batavia Biosciences B.V. (Netherlands)
• Altogen Biosystems (US)

Research Coverage:
This report provides a detailed picture of the viral vector and plasmid DNA manufacturing market. It aims at estimating the size and future growth potential of the market across different segments such as the type, product & service, workflow, application, disease indication, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges
The report provides insights on the following pointers:
• Analysis of key drivers (rising prevalence of genetic disorders, cancer, and infectious diseases, availability of funding for the development of gene therapy, effectiveness of viral vectors and ongoing research into viral vector-based gene and cell therapies), restraints (High operational costs associated with cell & gene therapy manufacturing and Short shelf-life of viral vectors), opportunities (Smart capital deployment and planning for scalability, and Leveraging digital to facilitate operational excellence), and challenges (Risk of mutagenesis and other unwanted outcomes, and Individual optimization and low yields hold back downstream processes) influencing the growth of the market.
• Product and Service Development/Innovation: Detailed insights on newly launched products & services, and technological assessment of the viral vector and plasmid DNA manufacturing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the viral vector and plasmid DNA manufacturing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and products and service offerings of leading players like Lonza Group AG (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), Catalent Inc. (US), WuXi AppTec (China), FUJIFILM Corporation (Japan), GenScript Biotech Corporation (US), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Novartis AG (Switzerland), Precision Biosciences (US), Bluebird Bio, Inc. (US), Sartorius AG (Germany), Danaher Corporation (US), SIRON Biotech (Germany), VGXI, Inc. (US), Waisman Biomanufacturing (US), Kaneka Eurogentec S.A. (Belgium), PlasmidFactory GmbH (Germany), ATUM (US), Addgene (US), Cell and Gene Therapy Catapult (UK), Batavia biosciences (Netherlands), and Altogen Biosystems (US)., and among others in the market.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.2.1 INCLUSIONS AND EXCLUSIONS 47
1.3 MARKET SCOPE 48
FIGURE 1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION 48
1.3.1 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 49
1.5 LIMITATIONS 49
1.6 STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 50
1.7.1 RECESSION IMPACT 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH APPROACH 52
FIGURE 2 RESEARCH DESIGN 52
2.1.1 SECONDARY RESEARCH 53
2.1.2 PRIMARY DATA 53
FIGURE 3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES 54
2.2 MARKET SIZE ESTIMATION 55
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022 55
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 56
FIGURE 6 ILLUSTRATIVE EXAMPLE OF LONZA GROUP AG: REVENUE SHARE ANALYSIS (2022) 56
2.2.1 INSIGHTS FROM PRIMARIES 58
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 58
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 58
2.3 GROWTH FORECAST 59
FIGURE 9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: CAGR PROJECTIONS 60
FIGURE 10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 11 DATA TRIANGULATION METHODOLOGY 61
2.5 RESEARCH ASSUMPTIONS 62
2.6 RISK ANALYSIS 62
2.7 RECESSION IMPACT ANALYSIS 62
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 62
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 63
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 63
3 EXECUTIVE SUMMARY 64
FIGURE 12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 64
FIGURE 13 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 65
FIGURE 14 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2023 VS. 2028 (USD MILLION) 65
FIGURE 15 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 66
FIGURE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION) 67
FIGURE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 67
FIGURE 18 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT 68
4 PREMIUM INSIGHTS 70
4.1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET OVERVIEW 70
FIGURE 19 ONGOING RESEARCH ON VIRAL VECTOR-BASED CELL AND GENE THERAPIES TO DRIVE MARKET 70
4.2 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: NORTH AMERICA, BY PRODUCT & SERVICE AND COUNTRY 71
FIGURE 20 PRODUCTS SEGMENT IN US ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 71
4.3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 71
FIGURE 21 PRODUCTS SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 71
4.4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SHARE, BY END USER (2022) 72
FIGURE 22 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 72
4.5 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 72
FIGURE 23 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 72
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 73
FIGURE 24 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 73
TABLE 4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 74
5.2.1 DRIVERS 74
5.2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases 74
5.2.1.2 Availability of funding for development of gene therapy 75
5.2.1.3 Effectiveness of viral vectors 76
5.2.1.4 Ongoing research on viral vector-based gene and cell therapies 76
TABLE 5 OVERVIEW OF CURRENT CLINICAL TRIALS BASED ON VECTOR TYPE 76
5.2.2 RESTRAINTS 77
5.2.2.1 High operational costs associated with cell and gene therapy manufacturing 77
5.2.2.2 Short shelf life of viral vectors 77
5.2.3 OPPORTUNITIES 78
5.2.3.1 Smart capital deployment and planning for scalability 78
5.2.3.2 Leveraging digital tools to facilitate operational excellence 78
5.2.4 CHALLENGES 79
5.2.4.1 Risk of mutagenesis and other unwanted outcomes 79
5.2.4.2 Individual optimization and low yield 79
5.3 INDICATIVE PRICING ANALYSIS 79
TABLE 6 PRICING ANALYSIS FOR PRODUCTS 80
5.4 VALUE CHAIN ANALYSIS 81
5.5 VALUE CHAIN ANALYSIS: MANUFACTURING PHASES ADD MAXIMUM VALUE 82
5.5.1 ECOSYSTEM ANALYSIS 82
FIGURE 25 ECOSYSTEM ANALYSIS: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 83
TABLE 7 OVERALL MARKET ECOSYSTEM FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 84
5.6 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.6.1 THREAT OF NEW ENTRANTS 86
5.6.2 THREAT OF SUBSTITUTES 86
5.6.3 BARGAINING POWER OF BUYERS 86
5.6.4 BARGAINING POWER OF SUPPLIERS 86
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.7 TECHNOLOGY ANALYSIS 87
TABLE 9 EXAMPLES OF ADVANCED PRODUCTS/PLATFORMS 87
5.8 PATENT ANALYSIS 88
FIGURE 26 TOP PATENT OWNERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, JANUARY 2014 TO JANUARY 2023 88
TABLE 10 EXAMPLES OF RECENT PATENT ACTIVITY IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 88
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURERS 89
5.10 REGULATORY ANALYSIS 90
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 94
TABLE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: LIST OF CONFERENCES AND EVENTS 94
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 95
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS 96
5.12.2 BUYING CRITERIA FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS AND SERVICES 96
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 97
6 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE 98
6.1 INTRODUCTION 99
TABLE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 99
6.2 VIRAL VECTOR 99
TABLE 18 VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 19 VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 20 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 21 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 22 ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 23 LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.2.1 RETROVIRUS 102
6.2.1.1 Rising application of retroviruses in gene therapy and gene transfer studies to support growth 102
TABLE 24 RETROVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 25 NORTH AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 26 EUROPE: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 27 ASIA PACIFIC: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 28 LATIN AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.2.2 ADENOVIRUS 104
6.2.2.1 Large capacity for carrying genetic material to promote growth 104
TABLE 29 ADENOVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 30 NORTH AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 31 EUROPE: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 32 ASIA PACIFIC: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 33 LATIN AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
6.2.3 ADENO-ASSOCIATED VIRUS 106
6.2.3.1 Low toxicity to support demand growth 106
TABLE 34 AAV VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 35 NORTH AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 36 EUROPE: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 37 ASIA PACIFIC: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 38 LATIN AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.2.4 LENTIVIRUS 108
6.2.4.1 Ability to infect both dividing and non-dividing cells to drive growth 108
TABLE 39 LENTIVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 40 NORTH AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 41 EUROPE: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 42 ASIA PACIFIC: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 43 LATIN AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.2.5 OTHER VIRAL VECTORS 110
TABLE 44 OTHER VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 45 NORTH AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 46 EUROPE: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 47 ASIA PACIFIC: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 48 LATIN AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
6.3 PLASMID DNA 113
6.3.1 GROWING R&D AND LAUNCHES OF PRODUCTION PLATFORMS TO BOOST MARKET 113
TABLE 49 PLASMID DNA MANUFACTURING MARKET, BY REGION 2021–2028 (USD MILLION) 113
TABLE 50 NORTH AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 51 EUROPE: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 53 LATIN AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
7 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE 115
7.1 INTRODUCTION 116
TABLE 54 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
7.2 PRODUCTS 116
7.2.1 INCREASING PRODUCT LAUNCHES TO DRIVE MARKET GROWTH 116
TABLE 55 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS, BY KEY PLAYER 117
TABLE 56 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 57 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 58 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 59 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 60 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
7.3 SERVICES 119
7.3.1 INCREASING DEMAND FOR SERVICES TO BOOST MARKET 119
TABLE 61 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES, BY KEY PLAYER 120
TABLE 62 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 63 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 64 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW 123
8.1 INTRODUCTION 124
TABLE 67 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 124
8.2 UPSTREAM MANUFACTURING 124
TABLE 68 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 125
TABLE 69 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 70 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 71 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 72 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 73 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
8.2.1 VECTOR AMPLIFICATION, EDITING, AND EXPANSION 127
8.2.1.1 Increasing demand for gene therapy to fuel growth 127
TABLE 74 VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 75 NORTH AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 76 EUROPE: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 77 ASIA PACIFIC: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 LATIN AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
8.2.2 VECTOR RECOVERY/HARVESTING 129
8.2.2.1 Rising clinical trials and approvals of cell and gene-based therapies to drive demand for vector recovery/harvesting 129
TABLE 79 VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 80 NORTH AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 81 EUROPE: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 ASIA PACIFIC: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 LATIN AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
8.3 DOWNSTREAM MANUFACTURING 131
TABLE 84 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 132
TABLE 85 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY REGION 2021–2028 (USD MILLION) 132
TABLE 86 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 87 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 88 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 89 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
8.3.1 PURIFICATION 134
8.3.1.1 Technological advancements in purification to drive market 134
TABLE 90 PURIFICATION PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 91 NORTH AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 92 EUROPE: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 93 ASIA PACIFIC: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 94 LATIN AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
8.3.2 FILL-FINISH 136
8.3.2.1 Technological advancements in downstream manufacturing process 136
TABLE 95 FILL-FINISH PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 96 NORTH AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 97 EUROPE: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 98 ASIA PACIFIC: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 99 LATIN AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION 139
9.1 INTRODUCTION 140
TABLE 100 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
9.2 CELL & GENE THERAPY 140
9.2.1 ROBUST PIPELINE FOR CELL & GENE THERAPY TO DRIVE MARKET 140
TABLE 101 NUMBER OF CELL AND GENE THERAPIES IN CLINICAL TRIAL PHASES (2021) 141
TABLE 102 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 103 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 104 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 105 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 106 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
9.3 VACCINE DEVELOPMENT 143
9.3.1 DEVELOPMENT OF NOVEL VACCINES TO DRIVE DEMAND FOR VIRAL VECTORS AND PLASMID DNA 143
TABLE 107 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY REGION 2021–2028 (USD MILLION) 143
TABLE 108 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 109 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 110 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 111 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 145
9.4 RESEARCH 145
9.4.1 RISING R&D TO INTRODUCE NEW APPLICATIONS OF VIRAL VECTOR AND PLASMID DNA 145
TABLE 112 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY REGION 2021–2028 (USD MILLION) 145
TABLE 113 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 114 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 115 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 116 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 147
10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION 148
10.1 INTRODUCTION 149
TABLE 117 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 149
10.2 CANCER 149
10.2.1 INCREASING PATIENT POPULATION TO PROPEL MARKET GROWTH 149
TABLE 118 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 150
TABLE 119 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 150
TABLE 120 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 121 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 122 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 123 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 152
10.3 GENETIC DISORDERS 152
10.3.1 LAUNCH OF ADVANCED TOOLS TO DELIVER THERAPEUTIC GENES TO SUPPORT MARKET GROWTH 152
TABLE 124 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 125 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 126 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 127 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 128 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
10.4 INFECTIOUS DISEASES 154
10.4.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 154
TABLE 129 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 130 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 131 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 132 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 133 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
10.5 OTHER DISEASE INDICATIONS 157
TABLE 134 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 135 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 136 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 137 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 138 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
11 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER 159
11.1 INTRODUCTION 160
TABLE 139 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 160
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 160
11.2.1 GROWING CELL & GENE THERAPY R&D TO BOOST GROWTH 160
TABLE 140 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 141 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 142 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 143 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 144 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 163
11.3 ACADEMIC & RESEARCH INSTITUTES 163
11.3.1 INCREASING DRUG DISCOVERY RESEARCH PROGRAMS TO DRIVE MARKET 163
TABLE 145 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 146 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 147 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 148 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 149 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 165
11.4 OTHER END USERS 165
TABLE 150 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 151 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 152 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 153 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 154 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION 168
12.1 INTRODUCTION 169
TABLE 155 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 169
12.2 NORTH AMERICA 169
12.2.1 NORTH AMERICA: RECESSION IMPACT 170
FIGURE 30 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SNAPSHOT 171
TABLE 156 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 157 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 158 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 159 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 172
TABLE 160 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 173
TABLE 161 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 173
TABLE 162 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 173
TABLE 163 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 164 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 174
TABLE 165 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 174
12.2.2 US 175
12.2.2.1 Increasing incidence of cancer to propel market 175
TABLE 166 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 167 US: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 168 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 176
TABLE 169 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 176
TABLE 170 US: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 177
TABLE 171 US: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 177
TABLE 172 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 173 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 178
TABLE 174 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 178
12.2.3 CANADA 178
12.2.3.1 Government initiatives to promote research to support market growth 178
TABLE 175 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 176 CANADA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 177 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 178 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 180
TABLE 179 CANADA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 180
TABLE 180 CANADA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 181
TABLE 181 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 182 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 181
TABLE 183 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3 EUROPE 182
12.3.1 EUROPE: RECESSION IMPACT 182
TABLE 184 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 185 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 186 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 187 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 184
TABLE 188 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 184
TABLE 189 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 190 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 191 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 192 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 186
TABLE 193 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 186
12.3.2 GERMANY 186
12.3.2.1 Presence of large number of academic research institutes to propel market 186
TABLE 194 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 195 GERMANY: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 196 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 188
TABLE 197 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 188
TABLE 198 GERMANY: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 188
TABLE 199 GERMANY: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 189
TABLE 200 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
TABLE 201 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 189
TABLE 202 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 190
12.3.3 UK 190
12.3.3.1 Increasing R&D investments by pharmaceutical companies to support market 190
TABLE 203 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 204 UK: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 205 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 191
TABLE 206 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 192
TABLE 207 UK: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 192
TABLE 208 UK: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 192
TABLE 209 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 193
TABLE 210 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 193
TABLE 211 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 193

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（end user）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21　10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.